Caspar Bang-Da Cunha

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 50 publications

Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia.

Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia.

Journal: Leukemia & lymphoma
Published: March 17, 2026

Effects of chronic lymphocytic leukaemia (CLL)-directed therapy on diffuse large B-cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort.

Effects of chronic lymphocytic leukaemia (CLL)-directed therapy on diffuse large B-cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort.

Journal: British journal of haematology
Published: March 12, 2026

CD20 negativity at the start of second-line therapy predicts a shorter overall survival in B-cell lymphomas.

CD20 negativity at the start of second-line therapy predicts a shorter overall survival in B-cell lymphomas.

Journal: Blood neoplasia
Published: December 29, 2025

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine
Published: December 08, 2025

Explainable machine learning to identify chronic lymphocytic leukemia and medication use based on gut microbiome data.

Explainable machine learning to identify chronic lymphocytic leukemia and medication use based on gut microbiome data.

Journal: Microbiology spectrum
Published: November 06, 2025

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial.

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial.

Journal: Blood
Published: October 22, 2025

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Journal: Blood
Published: October 22, 2025

Hypertension affects survival and treatment in chronic lymphocytic leukemia.

Hypertension affects survival and treatment in chronic lymphocytic leukemia.

Journal: Blood advances
Published: October 15, 2025

Hypertension Impacts Survival and Treatment in Chronic Lymphocytic Leukemia.

Hypertension Impacts Survival and Treatment in Chronic Lymphocytic Leukemia.

Journal: Blood advances
Published: October 15, 2025

Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial.

Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial.

Journal: The Lancet. Haematology
Published: June 17, 2025

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.

Journal: Blood
Published: February 24, 2025

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.

Journal: Blood advances
Published: October 25, 2024
Showing 1-12 of 50

Last Updated: 09/26/2026